• Explore /
  • Poster
  • / Overall survival (OS) with CPX-351 versus 7+3 in older adults with newly diagnosed, therapy-related acute myeloid leukemia (tAML): Subgroup analysis of a phase III study.

Overall survival (OS) with CPX-351 versus 7+3 in older adults with newly diagnosed, therapy-related acute myeloid leukemia (tAML): Subgroup analysis of a phase III study.

Abstract Poster

Authors

null

Jeffrey E. Lancet

H. Lee Moffitt Cancer Canter and Research Institute, Tampa, FL

Jeffrey E. Lancet , David Rizzieri , Gary J. Schiller , Robert K. Stuart , Jonathan E. Kolitz , Scott R. Solomon , Laura F. Newell , Harry Paul Erba , Geoffrey L. Uy , Robert Ryan , Michael Chiarella , Arthur Chin Louie , Jorge E. Cortes

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT01696084

Citation

J Clin Oncol 35, 2017 (suppl; abstr 7035)

DOI

10.1200/JCO.2017.35.15_suppl.7035

Abstract #

7035

Poster Bd #

235

Abstract Disclosures

Similar Posters

First Author: Jeffrey E. Lancet

First Author: Tara L. Lin

First Author: Ellen K. Ritchie

First Author: Tara L. Lin